Madrigal Pharmaceuticals Inc (MDGL)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

200 BARR HARBOR DRIVE, SUITE 400 WEST CONSHOHOCKEN, PA 19428

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing and commercializing small molecule drugs that address severe medical conditions with potential markets, including cancer and chronic inflammatory diseases. The Company has a pipeline of clinical and preclinical-stage drug candidates with distinct mechanisms of action and chemical structures. It retains all rights to all of its drug candidates and programs, across all geographic markets and therapeutic indications. The Company's most advanced clinical-stage drug candidate, STA-4783, is an injectable small molecule compound with a mechani® of action that has potential for the treatment of a range of solid tumor cancers. The Company's has discovered and developed three other drug candidates that are in clinical or pre-clinical development, each of which has a distinct chemical structure and mechani® of action.

Data as of 2020-11-22
Market Cap1.773 Billion Shares Outstanding15.438 Million Avg 30-day Volume130.185 Thousand
P/E Ratio-10.4 Dividend Yield EPS-11.07
Price/Sales Price cash flow ratio Price free cash flow ratio-15.4
Book Value18.73 Price to Tangible Book6.13 Alpha0.06
Short Interest Ratio % Short Interest to Float R-squared0.036322
BETA1.58289 52-week High/Low137.28 / 56.82 Stddev0.349997
View SEC Filings from MDGL instead.
Q3 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 2 2 0.0% 1 (0.07%) 1 (0.06%) 0.0%
Funds Holding: 122 125 -2.4% 34 (2.24%) 36 (2.34%) -5.56%
13F shares: 11.42 Million 11.116 Million 2.74% 6.418 Million 6.036 Million 6.32%
% Ownership 73.9717 72.0437 2.68% 41.5696 39.1196 6.26%
New Positions: 12 27 -55.56% 3 10 -70.0%
Increased Positions 40 45 -11.11% 12 13 -7.69%
Closed Positions 12 11 9.09% 5 4 25.0%
Reduced Positions 45 36 25.0% 15 11 36.36%
Total Calls 230.603 Thousand 235.671 Thousand -2.15% 171.932 Thousand 145.956 Thousand 17.8%
Total Puts 150.858 Thousand 130.828 Thousand 15.31% 36.4 Thousand 13.5 Thousand 169.63%
PUT/CALL Ratio 0.65 0.56 16.07% 0.21 0.09 133.33%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding MDGL (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding MDGL BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

BAY CITY CAPITAL LLC

BAY CITY CAPITAL MANAGEMENT IV LLC

BAY CITY CAPITAL FUND IV, L.P.

BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP

  • 10% Owner
2,310,521 2020-12-01 2

CRAVES FRED B

  • Director
  • 10% Owner
2,814,074 2020-09-04 5

LYNCH BRIAN JOSEPH SEE REMARKS

  • Officer
0 2020-08-06 2

GOLLUST KEITH R

  • Director
0 2020-06-17 1

MILLIGAN DAVID V

  • Director
0 2020-06-17 1

BATE KENNETH

  • Director
0 2020-06-17 1

LEVY RICHARD S

  • Director
0 2020-06-17 1

DALY JAMES M

  • Director
0 2020-06-17 1

SUKHIJA REMY SVP AND CHIEF COMM'L OFFICER

  • Officer
0 2020-04-01 1

FRIEDMAN PAUL A CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
0 2020-03-05 1

SCHNEEBAUM MARC R CHIEF FINANCIAL OFFICER

  • Officer
0 2020-03-05 1

TAUB REBECCA PRES., R&D, AND CMO

  • Officer
  • Director
0 2020-03-05 1

BAY CITY CAPITAL LLC

  • Director
  • 10% Owner
5,377,854 2018-06-11 2

RIEDER WENDY E FORMER SVP, GEN. COUNSEL

  • Officer
No longer subject to file 2016-07-22 0

SCHOR CHEN FORMER PRESIDENT AND CEO

  • Officer
  • Director
No longer subject to file 2016-07-22 0

MORENSTEIN SCOTT D

  • Director
17,857 2016-01-01 0

KOVNER BRUCE

  • Director
  • 10% Owner
21,712,805 2015-12-04 0

VUKOVIC VOJO SVP, CHIEF MEDICAL OFFICER

  • Officer
0 2015-10-02 0

WILSON ROBERT N

  • Director
760,936 2015-07-01 0

KUFE DONALD W

  • Director
0 2015-07-01 0

REARDON WILLIAM S

  • Director
49,392 2015-07-01 0

MCMAHON ARTHUR SVP, HUMAN RESOURCES

  • Officer
0 2015-03-02 0

WHITAKER ANNE CLEM PRESIDENT AND CEO

  • Officer
  • Director
0 2014-09-03 0

EHRLICH KEITH S VP, FIN. AND ADMIN., CFO

  • Officer
0 2014-03-03 0

BERNITZ STEVEN B SVP, CORPORATE DEVELOPMENT

  • Officer
25,000 2013-12-18 0

BAHCALL SAFI R PRESIDENT AND CEO

  • Officer
  • Director
2,533,135 2013-11-13 0

RAMACHANDRA SUMANT PRESIDENT, R&D

  • Officer
0 2013-03-11 0

SINGH AMAR SR. VP, CHIEF BUSINESS OFFICER

  • Officer
0 2013-03-05 0

KOYA KEIZO SR. VP, DRUG DEVELOPMENT

  • Officer
0 2012-03-06 0

CHEN LAN BO

  • Director
3,330,382 2010-12-31 0

BAILEY MICHAEL P SR. VP, CHIEF COMM. OFFICER

  • Officer
29,627 2010-08-05 0

CHADWICK JEREMY G SR. VP, PGM MGMT AND CLIN OPS

  • Officer
23,761 2010-03-01 0

CHEN LIN HUEY

  • 10% Owner
No longer subject to file 2009-12-31 0

BARSOUM JAMES G SR. VP, RESEARCH

  • Officer
0 2009-04-13 0

JACOBSON ERIC W SR. VP, RESEARCH AND CMO

  • Officer
0 2009-04-13 0

WILLIAMS MARTIN D SR. VP, BUSINESS DEV., CBO

  • Officer
0 2008-02-27 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

BAY CITY CAPITAL LLC - > 10% Owner see footnotes

BAY CITY CAPITAL MANAGEMENT IV LLC - > 10% Owner see footnotes

BAY CITY CAPITAL FUND IV, L.P. - > 10% Owner see footnotes

BAY CITY CAPITAL FUND IV CO INVESMENT FUND LP - > 10% Owner see footnotes

2020-12-01 21:36:43 -0500 2020-12-01 J 43,537 d 2,310,521 indirect

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

**EXPERIMENTAL** Current Active Short Positions

Get more info on our International short position coverage here

Holder Issuer Net Short Position Position Date Origin

Short Position History

Holder Net Short Position Position Date Origin
PDT Partners, LLC Madrigal Pharmaceuticals, Inc. 0.71% 2018-02-22 GERMANY
PDT Partners, LLC MADRIGAL PHARMACEUTICALS INC 0.57% 2018-03-05 GERMANY
PDT Partners, LLC Madrigal Pharmaceuticals, Inc. 0.63% 2018-02-15 GERMANY
PDT Partners, LLC Madrigal Pharmaceuticals, Inc. 0.5% 2018-02-12 GERMANY
PDT Partners, LLC Madrigal Pharmaceuticals, Inc. 0.69% 2018-02-26 GERMANY
PDT Partners, LLC MADRIGAL PHARMACEUTICALS INC 0.75% 2018-03-05 GERMANY
PDT Partners, LLC Madrigal Pharmaceuticals, Inc. 0.64% 2018-03-14 GERMANY

Elevate your investments